Page 6 - SLIDES
P. 6
CABOPRE: cabozantinib prior to cytoreductive nephrectomy
18 12wk ORR: 26.7%
cabozantinib 12wk PR: 26.7%
60mg x12wk
11 cytoreductive nephrectomy
1º outcome: ORR @12wk Med PFS: 12.7m
12m OS: 70%
Median follow up 9m
st
Cabozantinib is feasible as 1 line treatment for mRCC and
may enable selection for cytoreductive nephrectomy